N-(3-methoxyphenyl)benzene-1,2-diamine | 1033224-86-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: N-(3-methoxyphenyl)benzene-1,2-diamine
• 英文别名: 2-N-(3-methoxyphenyl)benzene-1,2-diamine
• CAS: 1033224-86-0
• 化学式: C₁₃H₁₄N₂O
• mdl: MFCD11202079
• 分子量: 214.267
• InChiKey: CETBAASDYUPKLL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.076
• 拓扑面积：
  47.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-(3-methoxyphenyl)benzene-1,2-diamine 在 氨基磺酸 、 磺酰胺 作用下， 以 二乙二醇二甲醚 为溶剂， 反应 0.5h， 生成 1-(3-methoxyphenyl)-1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide
  参考文献：
  名称：

  Discovery of Novel Selective Norepinephrine Reuptake Inhibitors: 4-[3-Aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols (WYE-103231)

  摘要：

  Structural modification of a virtual screening hit led to the identification of a new series of 4-[3-aryl-2,2-dioxido-2,1,3-benzothiadiazol-1(3H)-yl]-1-(methylamino)butan-2-ols which are potent and selective inhibitors of the norepinephrine transporter over both the serotonin and dopamine transporters. One representative compound S-17b (WYE-103231) had low nanomolar hNET potency (IC(50) = 1.2 nM) and excellent selectivity for hNET over hsERT (> 1600-fold) and hDAT (> 600-fold). S-17b additionally had a good pharmacokinetic profile and demonstrated oral efficacy in rat models of ovariectomized-induced thermoregulatory dysfunction and morphine dependent flush as well as the hot plate and spinal nerve ligation (SNL) models of acute and neuropathic pain.

  DOI：

  10.1021/jm100053t
• 作为产物：
  描述：

  (3-甲氧基-苯基)-(2'-硝基苯基)胺 在 铁粉 、 氯化铵 作用下， 以 乙醇 、 水 为溶剂， 反应 2.0h， 生成 N-(3-methoxyphenyl)benzene-1,2-diamine
  参考文献：
  名称：

  以二芳基胺为骨架的高效琥珀酸脱氢酶抑制剂的新型吡唑羧酰胺的设计，合成和抗真菌评价

  摘要：

  通过1 H NMR，13 C NMR和ESI-HRMS详细设计，合成和表征了16种带有二芳基胺骨架的新型吡唑羧酰胺。初步的生物分析结果表明，一些目标化合物对茄枯萎病菌，尖孢镰刀菌，疫疫霉和禾谷镰刀菌均表现出良好的抗真菌活性。其中，化合物1c表现出最高的体外抗sol。solani真菌活性，EC 50值为0.005 mg / L，优于市售的杀菌剂fluxapyroxad（EC 50  = 0.033 mg / L）。和化合物1c（IC 50  = 0.034 mg / L）显示出对琥珀酸脱氢酶的抑制能力高于fluxapyroxad（IC 50  = 0.037 mg / L）。这项研究表明，化合物1c可被视为潜在的琥珀酸脱氢酶抑制剂。

  DOI：

  10.1016/j.bmcl.2018.08.001

文献信息

• AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE
  申请人：McComas Casey Cameron

  公开号：US20080161366A1

  公开（公告）日：2008-07-03

  The present invention is directed to aminoalkyl-substituted aryl sulfamide derivatives of formula I: or a pharmaceutically acceptable salt, stereoisomer or tautomer thereof, which are monoamine reuptake inhibitors, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions, including, inter alia, vasomotor symptoms, sexual dysfunction, gastrointestinal disorders and genitourinary disorder, depression disorders, endogenous behavioral disorders, cognitive disorders, diabetic neuropathy, pain, and other diseases or disorders.

  本发明涉及公式I的氨基烷基取代芳基磺酰胺衍生物，或其药学上可接受的盐、立体异构体或互变异构体，它们是单胺再摄取抑制剂，包含这些衍生物的组合物，以及它们用于预防和治疗症状，包括但不限于血管运动症状、性功能障碍、胃肠障碍和泌尿生殖障碍、抑郁症、内源性行为障碍、认知障碍、糖尿病神经病变、疼痛和其他疾病或障碍的方法。
• 4-(Benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: Potent and selective p70S6 kinase inhibitors
  作者：Upul Bandarage、Brian Hare、Jonathan Parsons、Ly Pham、Craig Marhefka、Guy Bemis、Qing Tang、Cameron Stuver Moody、Steve Rodems、Sundeep Shah、Chris Adams、Jose Bravo、Emmanuelle Charonnet、Vladimir Savic、Jon H. Come、Jeremy Green

  DOI：10.1016/j.bmcl.2009.07.022

  日期：2009.9

  We report herein the design and synthesis of 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-amine derivatives as inhibitors of p70S6 kinase. Screening hits containing the 4-(benzimidazol-2-yl)-1,2,5-oxadiazol-3-ylamine scaffold were optimized for p70S6K potency and selectivity against related kinases. Structure-based design employing an active site homology model derived from PKA led to the preparation of benzimidazole 5-substituted compounds 26 and 27 as highly potent inhibitors (K-i < 1 nM) of p70S6K, with > 100-fold selectivity against PKA, ROCK and GSK3. (C) 2009 Elsevier Ltd. All rights reserved.
• WO2008/73459
  申请人：——

  公开号：——

  公开（公告）日：——